Breast cancer

Aggressive or slow-growing tumor? Contrast agent gives clues

A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing types.

“Doing both will help doctors find the right treatment,” said Zheng-Rong Lu, the M. Frank Rudy and Margaret Domiter Rudy Professor of Biomedical Engineering at Case Western Reserve and leader of the research. “There’s no such technology available now that we know of.”

Illustration of the concept of work. The targeted contrast agent, ZD2-Gd3N@C80,...
Illustration of the concept of work. The targeted contrast agent, ZD2-Gd3N@C80, binds to aggressive tumor and produces strong signal enhancement, but not in slow-growing tumors, which allow detection and risk-stratification of breast cancer.
Case Western Reserve University

The gadolinium-based agent is also more efficient and safer than traditional agents, requiring a gadolinium dose 20-times smaller, easily flushing from the body and leaving no accumulation in tissues, the researchers found in tests with mouse models. At the low dosage, the agent lights up cancer biomarkers during scans, overcoming the low sensitivity of MRI’s for imaging the markers. The research was published today (Sept. 25) in Nature Communications.

To make the agent, Lu and colleagues at Case Western Reserve combined commercially available tri-gadolinium nitride metallofullerene (Gd3N@C80), a highly efficient contrast agent, with a peptide labeled ZD2, which was developed in Lu’s lab.

Compared to the gadolinium used in traditional agents, Gd3N@C80’s “structure is different—the gadolinium ions are encaged in a hollow molecule of fullerene that looks like a soccer ball,” Lu said. “The cage prevents direct contact between the gadolinium and tissue, and the gadolinium will not be released, which prevents any kind of interaction with tissue. But the key technology for our targeted contrast agent is the peptide attached,” Lu said.

Photo
The figure shows the different expression of the biomarker (EDB-FN) and probe binding (ZD2) in slow-growing ER-positive breast cancer (not much yellow and red color representing low expression of the biomarker and low binding), and in triple- negative breast cancer (TNBC, high expression and high binding). As a result, the targeted contrast agent produced weak signal enhancement (brightness) in the former and strong signal (brightness) in the latter as pointed by the arrow. The technology is able to provide accurate detection and risk-stratification of aggressive BC.
Source: Case Western Reserve University

The lab applies ZD2 to the surface of the soccer ball. The peptide specifically targets the cancer protein extradomain-B fibronectin (EDB-FN). EDB-FN, which is associated with tumor invasion, metastasis and drug resistance, is highly expressed in the matrix around cancerous cells in many aggressive forms of human cancers.

In testing on six mouse models, MRI’s detected breast cancers in all cases. But the signal created by the accumulation of contrast molecules on three aggressive triple-negative breast cancers (MDA-MB-231, Hs578T and BT549) were significantly brighter. Because slow-moving ER-positive breast cancers (MCF-7, ZR-75-1 and T47D) produce less EDB-FN, fewer molecules attached. While detectible, the signal was muted.


Source: Case Western Reserve University

26.09.2017

Related articles

Advanced techniques

Breast cancer: how imaging technology will help avoid unnecessary biopsies

Enhancing the diagnosis of breast cancer is the stated goal of a research team at the German Cancer Research Center (DKFZ) in Heidelberg. The scientists have combined an advanced method of…

Manganese or gadolinium?

Promising first steps for alternative MRI contrast agent

NIH-supported researchers at Massachusetts General Hospital (MGH) are studying an alternative to the contrast agents currently used for magnetic resonance imaging. In a recent study, they showed that…

Animal testing

Can mice really mirror humans when it comes to cancer?

A new Michigan State University study is helping to answer a pressing question among scientists of just how close mice are to people when it comes to researching cancer. The findings, now published…

Related products

3 Tesla

Achieva 3.0 T X-series

Philips Healthcare

Accessories / Complementary systems

allMRI GmbH Foldable MRI wheelchair

allMRI GmbH

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Accessories / Complementary systems

GCTechnology CIRS Phantoms

GCTechnologyGmbH